✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Longevity · Peptide Reference

NAD+

Released: Last reviewed:

Coenzyme essential for cellular energy metabolism, DNA repair, and sirtuin activity. NAD+ levels decline with age. IV and SC NAD+ are used to restore cellular function; oral precursors (NR, NMN) are alternatives.

Longevity Evidence grade: B-C Not FDA-approved
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Key facts

Class
Coenzyme / dinucleotide
Routes
IV (most studied), SC, oral precursors
Pharmacy pathway
503A/503B for IV/SC; OTC for oral precursors
Side effects
Flushing, GI discomfort during infusion
Common stack
Methylated B vitamins
Common dose
50-200 mg SC daily or 500-1000 mg IV weekly
Evidence grade
B-C (mixed evidence; emerging clinical trials)
FDA status
Not FDA-approved (compounded for SC/IV)

Mechanism of action

Coenzyme essential for cellular energy metabolism, DNA repair, and sirtuin activity. NAD+ levels decline with age. IV and SC NAD+ are used to restore cellular function; oral precursors (NR, NMN) are alternatives.

Standard dosing

Typical clinical use: 50-200 mg SC daily or 500-1000 mg IV weekly. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. NAD+ requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved (compounded for SC/IV). FDA limits which peptides a pharmacy may compound; check this page’s dated FDA status notice before assuming a peptide is legally available. Ask which licensed pharmacy fills the prescription and check that pharmacy’s license with your state board of pharmacy.

U.S. telehealth providers prescribing NAD+

The most commonly cited U.S. telehealth providers for NAD+ are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD —, whose offerings for this peptide we have not verified (see the FDA status notice above). See the full provider directory for complete profiles.

Trade-offs to know

NAD+ carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved, cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that names its pharmacy, explains its follow-up schedule and states the regulatory status of what it prescribes.

Related peptides in the longevity category

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

References

  1. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689
  2. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PMID: 24786309
  3. Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochem Pharmacol. 2022;198:114946. PMID: 35114188

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.